JMCP Research Highlight: Prevalence of Opioid-Related Disorders in Medicare FFS Population
The prevalence of those diagnosed with opioid-related disorders in the Medicare fee-for-service (FFS) population — at 13.1 per 1,000 persons — is higher than among any other studied payer groups.
JMCP Adds Two Editors in Response to Growing Article Submissions
JMCP is pleased to announce the addition of two experienced managed care pharmacy experts to the JMCP editorial team.
Statement on FDA’s Proposed Guidance That Would Reclassify Insulin as a Biologic
AMCP CEO Susan A. Cantrell, RPh, CAE, issued a statement on the Food and Drug Administration’s release today of proposed guidance that would reclassify insulin as a biologic, as well as other guidances on biosimilars.
Foundation's 8th Annual Research Symposium Discusses Health Care Trends, Disruptors and Opportunities
Misaligned incentives that drive overutilization of certain treatments, a realization that everyone can't have everything, and the need to address social determinants to improve health were among the health care trends discussed.
AMCP Urges FDA to Issue Final Guidance on Biosimilar Interchangeability Standards
AMCP urges FDA to issue final guidance on interchangeability standards and develop educational materials on biosimilars.
AMCP Partnership Forum Examines Non-Traditional Payment and Benefit Models for High-Cost Pharmaceuticals
Experts at AMCP Partnership Forum agree new payment model are needed but a one-size-fits-all solution won’t work.
AMCP Explains PIE Act (H.R. 2026) in Info-Graphic
AMCP has prepared a one-page, easy-to-understand info-graphic on the PIE Act (H.R. 2026)
Emerging Trends Update: The Rx Affordability Crisis
The AMCP Foundation is pleased to present the second in a series of articles bridging the predictions from the Emerging Trends body of knowledge to current health care realities.
Drug Pricing Summary
AMCP has compiled a comprehensive summary of recent actions aimed at drug pricing by the White House, Congress and the states.